Ziprasidone 80 mg/day and 160 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 6-week placebo-controlled trial. Ziprasidone Study Group

Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology
D G DanielM Lakshminarayanan

Abstract

In this double-blind study, patients with an acute exacerbation of schizophrenia or schizoaffective disorder were randomized to receive either ziprasidone 80 mg/day (n = 106) or 160 mg/day (n = 104) or placebo (n = 92), for 6 weeks. Both doses of ziprasidone were statistically significantly more effective than placebo in improving the PANSS total, BPRS total, BPRS core items, CGI-S, and PANSS negative subscale scores (p < .05). Ziprasidone 160 mg/day significantly improved depressive symptoms in patients with clinically significant depression at baseline (MADRS > or = 14, over-all mean 23.5) (p < .05) as compared with placebo. The percentage of patients experiencing adverse events was similar in each treatment group, and resultant discontinuation was rare. The most frequent adverse events associated with ziprasidone were generally mild dyspepsia, nausea, dizziness, and transient somnolence. Ziprasidone was shown to have a very low liability for inducing movement disorders and weight gain. The results indicate that ziprasidone is effective and well tolerated in the treatment of the positive, negative, and depressive symptoms of an acute exacerbation of schizophrenia or schizoaffective disorder.

References

Dec 6, 2005·Psychopharmacology·C A JenningsE Southam
Feb 19, 2013·Psychopharmacology·Takefumi SuzukiDavid Mamo
Apr 7, 2005·European Archives of Psychiatry and Clinical Neuroscience·Hans-Jürgen Möller
Nov 4, 2005·European Archives of Psychiatry and Clinical Neuroscience·Michael RiedelHans-Jürgen Möller
Aug 22, 2001·European Journal of Pharmacology·A W SchmidtS H Zorn
Mar 26, 2003·Journal of Psychiatric Research·Ulrich ZimmermannThomas Pollmächer
Aug 18, 2001·Pharmacology, Biochemistry, and Behavior·R S MansbachS H Zorn
Dec 31, 2002·Psychoneuroendocrinology·R Tandon, M D Jibson
Dec 31, 2002·Psychoneuroendocrinology·H Nasrallah
Aug 2, 2003·Schizophrenia Research·Patrick W CorriganGregory A Toombs
May 27, 2003·Schizophrenia Research·S Charles SchulzMartin Brecher
Oct 6, 2001·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·John M Kane
Mar 7, 2006·Nature Reviews. Drug Discovery·T Scott StroupJeffrey A Lieberman
Oct 21, 2005·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Laurent BardinAdrian Newman-Tancredi
Nov 18, 2005·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Abegale W HartfieldPeter G Clifton
Oct 31, 2003·The New England Journal of Medicine·Robert Freedman
Oct 12, 2013·Journal of Child and Adolescent Psychopharmacology·Robert L FindlingMelissa P DelBello
Jan 11, 2008·Schizophrenia Bulletin·Robert P McMahonWilliam T Carpenter
May 23, 2002·Clinical Neuropharmacology·Robert L Rodnitzky
Mar 14, 2000·Journal of the American Academy of Child and Adolescent Psychiatry·F R SalleeP B Chappell
Aug 8, 2002·Journal of the American Academy of Child and Adolescent Psychiatry·Christopher J McDougleDavid J Posey
Jan 25, 2003·Journal of the American Academy of Child and Adolescent Psychiatry·Sarah B SchurPeter S Jensen
Mar 17, 2001·International Clinical Psychopharmacology·John M Kane
Mar 17, 2001·International Clinical Psychopharmacology·D E Casey
Apr 23, 2004·International Clinical Psychopharmacology·D G DanielE P Harrigan
Feb 25, 2005·International Clinical Psychopharmacology·Ronald R Brown, Michael W Estoup
Dec 5, 2000·Behavioural Pharmacology·B Scatton, D J Sanger
Dec 1, 2005·International Clinical Psychopharmacology·John M KaneEarl Giller
Dec 1, 2005·International Clinical Psychopharmacology·Dimitris XomalisKostas Fokas
Mar 11, 2006·International Clinical Psychopharmacology·Jean-Pierre OliéRuoyong Yang
Mar 18, 2008·Journal of Clinical Psychopharmacology·Keming GaoJoseph R Calabrese
May 27, 2010·Clinical Neuropharmacology·Sung-Wan KimJin-Sang Yoon
Jan 5, 2002·Current Medical Research and Opinion·B Green

Related Concepts

Antipsychotic Effect
Schizophrenia
Piperazines
Ziprasidone
Acute Disease
Adverse Event
Dizziness
Ziprasidone 80 MG
Nausea
Depressive Symptoms

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Synapse Loss as Therapeutic Target in MS

As we age, the number of synapses present in the human brain starts to decline, but in neurodegenerative diseases this occurs at an accelerated rate. In MS, it has been shown that there is a reduction in synaptic density, which presents a potential target for treatment. Here is the latest research on synapse loss as a therapeutic target in MS.

Artificial Intelligence in Cardiac Imaging

Artificial intelligence (ai) techniques are increasingly applied to cardiovascular (cv) medicine in cardiac imaging analysis. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

Social Learning

Social learning involves learning new behaviors through observation, imitation and modeling. Follow this feed to stay up to date on the latest research.

Cell Atlas of the Human Eye

Constructing a cell atlas of the human eye will require transcriptomic and histologic analysis over the lifespan. This understanding will aid in the study of development and disease. Find the latest research pertaining to the Cell Atlas of the Human Eye here.

Single Cell Chromatin Profiling

Techniques like ATAC-seq and CUT&Tag have the potential to allow single cell profiling of chromatin accessibility, histones, and TFs. This will provide novel insight into cellular heterogeneity and cell states. Discover the latest research on single cell chromatin profiling here.

Genetic Screens in iPSC-derived Brain Cells

Genetic screening is a critical tool that can be employed to define and understand gene function and interaction. This feed focuses on genetic screens conducted using induced pluripotent stem cell (iPSC)-derived brain cells.